Canagliflozin Improves Anemia in Renal Disease

Categorieën: Gezondheid | Welzijn Gezondheid Opvoeding Leeftijd: 14 t/m 18 jaar 19 t/m 30 jaar 31 t/m 64 jaar

Laden...

4 jaren geleden

Html
Tekst

Plus: FDA approves Zegalogue for hypoglycemia treatment; benefits of early morning eating; more

Saturday, March 27, 2021 : Issue #1118

TOP STORIES - Diabetes News & Research

Canagliflozin Linked to Improved Anemia in Patients with Diabetes and Renal Disease
Fluctuations in Waist Circumference Linked to Cardiovascular Outcomes
Does Age at Diagnosis in Familial Diabetes Affect Type 2 Risk?

Letter from the Editor
There is no doubt that the side effect endpoints a pharma company has to evaluate when they bring a new drug to market have increased over the past 15 years. We often mention that if some of the older diabetes medications had to go through the rigorous studies required today, most of them would have never made it onto the pharmacy shelves.
Although these studies are looking for side effects they oftentimes reveal positive effects for our patients. Last week we had a feature on how GLP-1RAs show positive results for use in type 1 patients. Another of these classes of drugs that has borne extra fruit is the SGLT-2 inhibitors. They were first approved for glucose control, but when further data was analyzed we found they helped with hypertension, kidney failure, and weight loss. This week our intern, Adrian Gavre, PharmD Candidate, Philadelphia College of Osteopathic Medicine, discusses the relationship of SGLT-2 inhibitors and anemia in renally challenged patients with diabetes. Take a look here at our Laterpay feature to learn what else these "diabetes" drugs can do.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief

Newsflash: FDA OKs dasiglucagon pen for hypoglycemia treatment

The FDA has approved Zealand Pharma's Zegalogue injection 0.6 mg as a treatment for patients aged 6 and above with severe hypoglycemia. Three trials involving diabetes patients who used the dasiglucagon injection showed they attained blood glucose recovery from severe hypoglycemia with a median time of 10 minutes. See news release.

Did You Know? Eating Before 8:30AM Reduces Risk Factors for Type 2 Diabetes:

According to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting, people who start eating before 8:30 a.m. had lower blood sugar levels and less insulin resistance, which could reduce the risk of developing type 2 diabetes, regardless of whether they restricted their food intake to less than 10 hours a day or their food intake was spread over more than 13 hours daily.
Previous studies have found that time-restricted eating, which consolidates eating to a shortened timeframe each day, has demonstrated improvement in metabolic health; researchers wanted to assess whether eating earlier in the day affected metabolic measures.
The researchers analyzed data from 10,575 adults who participated in the National Health and Nutrition Examination Survey. They divided participants into three groups depending on the total food intake duration: less than 10 hours, 10-13 hours, and more than 13 hours per day. They then created six subgroups based on eating duration start time (before or after 8:30 a.m.).
They analyzed this data to determine if eating duration and timing were associated with fasting blood sugar levels and estimated insulin resistance. Fasting blood sugar levels did not differ significantly among eating interval groups. Insulin resistance was higher with shorter eating interval duration but lower across all groups with an eating start time before 8:30 a.m.
These findings suggest that timing is more strongly associated with metabolic measures than duration and support early eating strategies.
ScienceDaily, March 18, 2021

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Alexandria Bartley, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences

Alexis Dunn, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences

Adrian Gavre, PharmD Candidate, Philadelphia College of Osteopathic Medicine

George McConnell, PharmD. Candidate, LECOM School of Pharmacy

Shadrielle Robbins, PharmD Candidate, South College School of Pharmacy

Mit Suthar, PharmD. Candidate, LECOM School of Pharmacy

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com

©2021 HIPER, LLC. All rights reserved.
This email was sent by eHealthcare Solutions on behalf of: Diabetes In Control
2093 Philadelphia Pike #8370
Claymont, DE, 19703, United States
DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe

Deel deze op

Laden...

Andere nieuwsbrieven van Diabetesincontrol.com

FDA Approves New Drugs to Treat Type 2 Diabetes in Children Diabetesincontrol.com
2 jaren geleden
What's the Role of Gene Therapy in Type 2 Diabetes Management? Diabetesincontrol.com
2 jaren geleden
Can Intermittent Fasting Achieve Remission in Type 2 Diabetes? Learn Here. Diabetesincontrol.com
2 jaren geleden

Meer nieuwsbrieven van Diabetesincontrol.com

Laden...

Gerelateerde nieuwsbrieven

Bekijk andere categorieën

Gezondheid | Welzijn Gezondheid Opvoeding

Canagliflozin Improves Anemia in Renal Disease

Saturday, March 27, 2021 : Issue #1118

TOP STORIES - Diabetes News & Research

Newsflash: FDA OKs dasiglucagon pen for hypoglycemia treatment

TOP STORIES - Diabetes News and Research

Did You Know? Eating Before 8:30AM Reduces Risk Factors for Type 2 Diabetes:

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Deel deze op

Andere nieuwsbrieven van Diabetesincontrol.com

Gerelateerde nieuwsbrieven

Bekijk andere categorieën